Milsaperidone (VHX-896) vs Ziprasidone
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Milsaperidone (VHX-896)
Marketed by Vanda Pharmaceuticals
NCT06494397 · Phase 1 · completed
Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.
No aligned efficacy figure on record for this race.
Ziprasidone
Marketed by Viatris and partners
NCT00159770 · Phase 3 · completed
This 12-week, open-label, multicentre trial randomized 293 patients with chronic schizophrenia to ziprasidone (n=147) or to a comparator group of olanzapine, risperidone or quetiapine chosen by the investigator (n=146). The primary endpoint was total PANSS score, tested for non-inferiority with a margin of 7 points to the disadvantage of ziprasidone. Ziprasidone was non-inferior to the comparator group on total PANSS and on all subscores (P<0.0001), so the primary endpoint was met. The figures come from the peer-reviewed paper (Lublin et al., World J Biol Psychiatry 2009), whose abstract does not give a confidence interval.
Next expected readout: February 2027 · NCT03781115 (registry estimate)
Reported efficacy
Number of Events Recorded Based on Ziprasidone Side Effects Checklist During Randomized Trial (From Baseline up to Week 8); Change From Baseline in Simpson Angus Scale for Extrapyramidal Symptoms (SAS) (Baseline, Week 2, Week 4, Week 6, Week 8); Change From Baseline in the Barnes Akathisia Scale (BAS) (Baseline, Week 2, Week 4, Week 6, Week 8); Number of Participants With High and Low Levels in Serum Prolactin Concentration (Baseline, Week 8); Vital Signs: Systolic and Diastolic Blood Pressure Levels (Baseline, Week 1, Week 2, Week 4, Week 6, Week 8); Electrocardiogram (EKG): Number of Participants With an Increase From Baseline to Corrected QT (QTc) Interval >/= 500 Milliseconds (Msec) (6 hours after dosing of Weeks 1, 2 and 8); Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline, Week 2, Week 4, Week 6, Week 8); Percentage of Participants With Response (Baseline, Week 2, Week 4, Week 6, Week 8); Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Score (Baseline, Week 2, Week 4, Week 6, Week 8); Number of Treatment-emergent Adverse Events During Randomized Trial (From Baseline up to Week 8): Change from baseline in PANSS total score at Week 8, high-dose ziprasidone (320 mg/day) vs standard dose (160 mg/day plus placebo capsules): -8.62 vs -5.48, mixed-model difference -1.37 (95% CI -7.20 to 4.45), p=0.642. No registered primary favoured the high dose; the Simpson-Angus extrapyramidal score was worse on the high dose at Week 2 (difference 1.02, 95% CI 0.08 to 1.95, p=0.033). (missed)
Result source: NCT00403546
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Milsaperidone (VHX-896) | Ziprasidone |
|---|---|---|
| PANSS total, change | —Not reported | —Not posted · NCT00159770 |
| CGI-S, change | —Not reported | -1.2 vs -1.2vs HaloperidolNCT00723606 |
| PANSS response | —Not reported | —Not posted · NCT00159770 |
| PSP, change | —Not reported | —Not posted · NCT00159770 |
| Relapse (% of patients) | —Not reported | —Not posted · NCT00159770 |
PANSS total, change
- Milsaperidone (VHX-896)
- —Not reported
- Ziprasidone
- —Not posted · NCT00159770
CGI-S, change
- Milsaperidone (VHX-896)
- —Not reported
- Ziprasidone
- -1.2 vs -1.2vs HaloperidolNCT00723606
PANSS response
- Milsaperidone (VHX-896)
- —Not reported
- Ziprasidone
- —Not posted · NCT00159770
PSP, change
- Milsaperidone (VHX-896)
- —Not reported
- Ziprasidone
- —Not posted · NCT00159770
Relapse (% of patients)
- Milsaperidone (VHX-896)
- —Not reported
- Ziprasidone
- —Not posted · NCT00159770
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Milsaperidone (VHX-896): no structured comparison results are available for Schizophrenia.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Milsaperidone (VHX-896): 0 of 4 rows · Ziprasidone: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ziprasidone |
|---|---|
| Dropout rate | —High dosea NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3 show 9 more results—High dose NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3 26.8% NCT00338949 · Phase 4 · registry result, not featured evidence 58.5% NCT00406315 · Phase 4 · registry result, not featured evidence 12.5% NCT00351000 · Phase 4 · registry result, not featured evidence 2.1% NCT00723606 · Phase 3 · registry result, not featured evidence 99.1% NCT00139737 · Phase 3 · registry result, not featured evidence 88.4% NCT00174447 · Phase 3 · registry result, not featured evidence 35.7% NCT00538642 · Phase na · registry result, not featured evidence 0% NCT00225498 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | —High dosea NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3 show 9 more results—High dose NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3 — NCT00338949 · Phase 4 · registry result, not featured evidence 16.2% NCT00406315 · Phase 4 · registry result, not featured evidence — NCT00351000 · Phase 4 · registry result, not featured evidence 1.1% NCT00723606 · Phase 3 · registry result, not featured evidence 16.9% NCT00139737 · Phase 3 · registry result, not featured evidence 44.2% NCT00174447 · Phase 3 · registry result, not featured evidence — NCT00538642 · Phase na · registry result, not featured evidence — NCT00225498 · Phase na · registry result, not featured evidence |
| Serious AEs | —High dosea NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3 show 9 more results10.5%High dose NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3 6.7% NCT00338949 · Phase 4 · registry result, not featured evidence 9.1% NCT00406315 · Phase 4 · registry result, not featured evidence 0% NCT00351000 · Phase 4 · registry result, not featured evidence 0% NCT00723606 · Phase 3 · registry result, not featured evidence 9.7% NCT00139737 · Phase 3 · registry result, not featured evidence 30.2% NCT00174447 · Phase 3 · registry result, not featured evidence 0% NCT00538642 · Phase na · registry result, not featured evidence 0% NCT00225498 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | High dosea hypertension 18.4% somnolence 15.8% headache 10.5% NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3 show 6 more resultsinsomnia 19.1% somnolence 14.5% nausea 11.6% NCT00406315 · Phase 4 · registry result, not featured evidence difficulty breathing 4.2% dizziness 4.2% NCT00351000 · Phase 4 · registry result, not featured evidence dizziness 3.7% somnolence 3.7% akathisia 3.2% NCT00723606 · Phase 3 · registry result, not featured evidence electrocardiogram qt prolonged 13.9% insomnia 6.3% anxiety 4.5% NCT00139737 · Phase 3 · registry result, not featured evidence anxiety 23.3% insomnia 16.3% schizophrenia 14% NCT00174447 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 8 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ziprasidone
show 3 more results
show 3 more results
show 1 more result
show 1 more result
show 2 more results
+ 21 further endpoints in the CSV export.
Bipolar Disorder
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Bipolar Disorder pipeline
Milsaperidone (VHX-896)
Marketed by Vanda Pharmaceuticals
NCT06494397 · Phase 1 · completed
Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.
No aligned efficacy figure on record for this race.
Ziprasidone
Marketed by Viatris and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Bipolar Disorder
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Milsaperidone (VHX-896): no structured comparison results are available for Bipolar Disorder.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ziprasidone
Available safety results
Ziprasidone
| Dropout rate | — NCT00421954 · Phase 3 · registry result, not featured evidence show 1 more result35.7% NCT00538642 · Phase na · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | — NCT00421954 · Phase 3 · registry result, not featured evidence show 1 more result— NCT00538642 · Phase na · registry result, not featured evidence |
| Serious AEs | — NCT00421954 · Phase 3 · registry result, not featured evidence show 1 more result0% NCT00538642 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | — |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Milsaperidone (VHX-896)'s landscape · Ziprasidone's landscape